Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Trastuzumab × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 46 Stomach Neoplasms 10 Neoplasm Metastasis 6 Esophageal Neoplasms 6 Neoplasms 5 Colorectal Neoplasms 4 Adenocarcinoma Of Esophagus 4 Colonic Neoplasms 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Rectal Neoplasms 2 Multiple Myeloma 2 Meningeal Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Inflammatory Breast Neoplasms 2 HER2-positive Gastric Cancer 2 HER2-positive Early Breast Cancer 2 HER2-positive Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Anatomic Stage I Breast Cancer AJCC v8 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Solid Cancer 1 Salivary Gland Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Prostatic Neoplasms 1 Patient Preference 1 Pathologic Complete Response 1

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡